ГАСТРОЭЗОФАГЕАЛЬНЫЙ РЕФЛЮКС: НОВЫЕ ПЕРСПЕКТИВЫ ЛЕЧЕНИЯ

С. С. Кардашева; Ю. О. Шульпекова; В. И. Лещенко

doi:10.21518/2079-701X-2017-11-92-99

ГАСТРОЭЗОФАГЕАЛЬНЫЙ РЕФЛЮКС: НОВЫЕ ПЕРСПЕКТИВЫ ЛЕЧЕНИЯ

С. С. Кардашева, Ю. О. Шульпекова, В. И. Лещенко

https://doi.org/10.21518/2079-701X-2017-11-92-99

Полный текст:

PDF (Rus)

Аннотация

В статье представлены данные эпидемиологических исследований по распространенности симптомов гастроэзофагеальной рефлюксной болезни (ГЭРБ), факторы риска и проявления ГЭРБ. Особое внимание уделено индивидуальному терапевтическому подходу и выбору современного эффективного средства для лечения – ИПП декслансопразола.

Ключевые слова

гастроэзофагеальная рефлюксная болезнь, неэрозивная рефлюксная болезнь, эрозивный эзофагит, терапия, ИПП, декслансопразол

Об авторах

С. С. Кардашева

Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
Кандидат медицинских наук

Ю. О. Шульпекова

Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия

Кандидат медицинских наук

В. И. Лещенко

Список литературы

1. Ивашкин В.Т., Шептулин А.А., Трухманов А.С., Маев И.В. и др. Гастроэзофагеальная рефлюксная болезнь. Клинические рекомендации по диагностике и лечению. М., 2014. 31 с.

2. Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity. Gastroenterology, 2017 May, 152(7): 1656-1670. doi: 10.1053/j.gastro.2016.12.052.

3. Vaishnav B, Bamanikar A, Maske P, Reddy A, Dasgupta S. Gastroesophageal Reflux Disease and its Association with Body Mass Index: Clinical and Endoscopic Study. J Clin Diagn Res, 2017 Apr, 11(4): OC01-OC04. doi: 10.7860/JCDR/2017/24151.9562.

4. Lee SW, Lee TY, Lien HC, Peng YC, Yeh HJ, Chang CS. Correlation Between Symptom Severity and Health-Related Life Quality of a Population With Gastroesophageal Reflux Disease. Gastroenterology Res, 2017 Apr, 10(2): 78-83. doi: 10.14740/gr753w.

5. Ida T, Inamori M, Inoh Y, Fujita K, Hamanaka J, Chiba H, Kusakabe A, Morohashi T, Goto T, Maeda S.Clinical Characteristics of Severe Er osive Esophagitis among Patients with Erosive Esophagitis: A Case-control Study. Intern Med, 2017, 56(11): 1293-1300. doi: 10.2169/internalmedicine.56.8058.

6. Filiberti RA, Fontana V, De Ceglie A, Blanchi S, Grossi E, Della Casa D, Lacchin T, De Matthaeis M, Ignomirelli O, Cappiello R, Rosa A, Foti M, Laterza F, D’Onofrio V, Iaquinto G, Conio M. Alcohol consumption pattern and risk of Barrett’s oesophagus and erosive oesophagitis: an Italian case-control study. Br J Nutr, 2017 May 8: 1-11. doi: 10.1017/S0007114517000940.

7. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol, 2013, 108: 308.

8. Li XQ, Andersson TB, Ahlström M, Weidolf LComparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos, 2004 Aug, 32(8): 821-7.

9. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitor: an update. Drug Saf, 2014 Apr, 37(4): 201-11. doi: 10.1007/s40264-014-0144-0.

10. BMS. Plavix prescribing information. 2011. http://products.sanofi.us/plavix/plavix.html. Last accessed 23 April 2012.

11. Andersson T, Weidolf L. Stereoselective disposition of proton pump inhibitors. Clin Drug Investig, 2008, 28(5): 263-79.

12. Mermelstein J, Mermelstein АС, Chait ММ. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole. Clin Exp Gastroenterol, 2016, 9: 163-172.

13. Hershcovici T, Jha LK, Fass R. Dexlansoprazole MR – a review. Ann Med, 2011, 43(5): 366–374.

14. Kukulka M, Eisenberg C, Nudurupati S. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin Exp Gastroenterol, 2011, 4(4): 213–220.

15. Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor – evidence for dosing flexibility. Aliment Pharmacol Ther, 2009, 29(8): 824–833.

16. Lee RD, Mulford D, Wu J, Atkinson SN. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor. Aliment Pharmacol Ther, 2010, 31(9): 1001–1011.

17. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation – results from two randomized controlled studies. Aliment Pharmacol Ther, 2009, 29(7): 731–741.

18. Peura DA, Pilmer B, Hunt B, Mody R, Perez MC. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Aliment Pharmacol Ther, 2013, 37(8): 810–818.

19. Metz DC, Howden CW, Perez MC, Larsen L, O’Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther, 2009, 29(7): 742–754.

20. Iwakiri K, Sakurai Y, Shiino M, Okamoto H, Kudou K, Nishimura A, Hiramatsu N, Umegaki E, Ashida K. A randomized, doubleblind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resist-ant erosive esophagitis. Therap Adv Gastroenterol, 2017 Jun, 10(6): 439-451. doi: 10.1177/1756283X17705329.

21. Johnson DA, Oldfield EC. Reported Side Effects and Complications of Long-term Proton Pump Inhibitor Use. Clin Gastroenterol Hepatol, 2013, 11(5): 458-464.

22. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol, 2009, 104(Suppl 2): S5–S9.

23. Sarzynski E, Puttarajappa C, Xie Y, et al. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci, 2011, 56: 2243–2253.

24. Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res, 2010, 25: 2205–2211.

25. Hansen KE, Jones AN, Lindstrom JM, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res, 2010, 25: 2510–2519.

26. Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol, 2012, 107: 1361–1369.

27. Mizunashi K, Furukawa Y, Katano K, et al. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int, 1993, 53: 21–25.

28. Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of protonpump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol, 2012, 5: 219–232.

29. Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol, 2013 Aug 10, 167(3): 965-74. doi: 10.1016/j.ijcard.2012.03.085.

30. Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol, 2011, 107: 871–878.

31. Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol, 2009, 104: 1130–1134.

32. Haastrup PF, Paulsen MS, Christensen RD, Søndergaard J, Hansen JM, Jarbøl DE. Medical and non-medical predictors of initiating longterm use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. Aliment Pharmacol Ther, 2016 Jul, 44(1): 78-87.

33. Инструкция по применению лекарственного препарата для медицинского применения Дексилант®. Рег.уд. ЛП 002477 от 26.05.14.